0000905718-13-000021.txt : 20130211 0000905718-13-000021.hdr.sgml : 20130211 20130211165332 ACCESSION NUMBER: 0000905718-13-000021 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20130211 DATE AS OF CHANGE: 20130211 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ONCOGENEX PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000949858 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 954343413 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-45969 FILM NUMBER: 13592538 BUSINESS ADDRESS: STREET 1: 1522 217TH PLACE S.E. CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254879500 MAIL ADDRESS: STREET 1: 1522 217TH PLACE S.E. CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: SONUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19950825 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Abingworth LLP CENTRAL INDEX KEY: 0001397144 IRS NUMBER: 980518585 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 38 JERMYN STREET CITY: LONDON STATE: X0 ZIP: SW1Y 6DN BUSINESS PHONE: 44 (0)20 7534 1500 MAIL ADDRESS: STREET 1: 38 JERMYN STREET CITY: LONDON STATE: X0 ZIP: SW1Y 6DN SC 13G/A 1 oncog13gam2dec12.htm AMENDMENT NO. 2 oncog13gam2dec12.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
SCHEDULE 13G
 
 
Under the Securities Exchange Act of 1934
 
(Amendment No. 2)*
 
 
OncoGenex Pharmaceuticals, Inc.
(Name of Issuer)
 
Common Stock, $0.001 par value per share
(Title of Class of Securities)
 
68230A106
(CUSIP Number)
 
December 31, 2012
(Date of Event Which Requires Filing of this Statement)
 
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
 
[   ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[   ] Rule 13d-1(d)
 
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
 
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
 

 
 
 
 

 
CUSIP No. 68230A106                     13G                       Page 2 of 5
 
 
 
1
NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
Abingworth LLP
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) [   ]
   
(b) [   ]
 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
England
 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
5
SOLE VOTING POWER:   0
 
6
SHARED VOTING POWER:   603,740*
 
7
SOLE DISPOSITIVE POWER:   0
 
8
SHARED DISPOSITIVE POWER:   603,740*
 
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
603,740*
 
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
[ ]
 
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.1%*
 
12
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN
 
 
* Beneficial ownership percentage is based upon 14,656,916 shares of common stock, $0.001 par value per share (“Common Stock”), of OncoGenex Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”), issued and outstanding as of November 7, 2012, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2012 (File No. 033-80623), filed with the Securities and Exchange Commission on November 8, 2012. Abingworth LLP (the “Reporting Person”) is the investment manager to a number of investment funds that include Abingworth Bioventures V L.P. (“ABV V”) and Abingworth Bioequities Master Fund Limited (“ABE” and, together with ABV V, the “Abingworth Funds”). As of December 31, 2012, ABV V is the owner of record of 396,104 shares of Common Stock and ABE is the owner of record of 207,636 shares of Common Stock. The Reporting Person, as the investment manager to the Abingworth Funds, may be deemed to beneficially own the 603,740 shares of Common Stock held by the Abingworth Funds. This report shall not be deemed an admission that the Reporting Person, either of the Abingworth Funds or any other person is the beneficial owner of the securities reported herein for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
 
 
 
 
 
 
 
 
 
CUSIP No. 68230A106                      13G                       Page 3 of 5
 
Item 1(a).
Name of Issuer:   OncoGenex Pharmaceuticals, Inc. (the “Issuer”).
 
Item 1(b).
Address of Issuer’s Principal Executive Offices:
 
1522 217th Place SE, Suite 100, Bothell, Washington 98021.
 
Item 2(a).
Name of Persons Filing:  This Schedule 13G, as amended, is being filed by Abingworth LLP (the “Reporting Person”). The Reporting Person is the investment manager to a number of investment funds that include Abingworth Bioventures V L.P. (“ABV V”) and Abingworth Bioequities Master Fund Limited (“ABE” and, together with ABV V, the “Abingworth Funds”). As of  December 31, 2012, ABV V is the owner of record of 396,104 shares of the Issuer’s common stock, par value $0.001 per share (“Common Stock”), and ABE is the owner of record of 207,636 shares of Common Stock. The Reporting Person, as the investment manager to the Abingworth Funds, may be deemed to beneficially own the 603,740 shares of Common Stock held by the Abingworth Funds.
 
Item 2(b).
Address of Principal Business Office or, if None, Residence:   The business address for the Reporting Person is Princes House, 38 Jermyn Street, London, England SW1Y 6DN.
 
Item 2(c).
Citizenship:   Abingworth LLP is a limited liability partnership organized under the laws of England.
 
Item 2(d).
Title of Class of Securities:   Common Stock, $0.001 par value per share.
 
Item 2(f).
CUSIP Number:   68230A106
 
Item 3.
If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person filing is a:
 
Not applicable.
 
Item 4.
Ownership.
 
          (a)   Amount Beneficially Owned (as of December 31, 2012):   603,740*
 
          (b)   Percent of Class (as of December 31, 2012):   4.1%*
 
          (c)   Number of Shares as to which such person has:
 
          (i)   sole power to vote or to direct the vote:   0
 
          (ii)   shared power to vote or to direct the vote:   603,740*
 
          (iii)   sole power to dispose or to direct the disposition:   0
 
          (iv)   hared power to dispose or to direct the disposition:   603,740*
 
 
*
Beneficial ownership percentage is based upon 14,656,916 shares of Common Stock issued and outstanding as of November 7, 2012, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2012 (File No. 033-80623), filed with the Securities and Exchange Commission on November 8, 2012. The Reporting Person is the investment manager to a number of investment funds that include ABV V and ABE. As of December 31, 2012, ABV V is the owner of record of 396,104 shares of Common Stock and ABE is the owner of record of 207,636 shares of Common Stock. The Reporting Person, as the investment manager to the Abingworth Funds, may be deemed to beneficially own the 603,740 shares of Common Stock held in the aggregate by the Abingworth Funds. This report shall not be deemed an admission that the Reporting Person, either of the Abingworth Funds or any other person is the beneficial owner of the securities reported herein for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
 
 
 
 
 
 
 
 
CUSIP No. 68230A106                   13G                          Page 4 of 5
 
 
Item 5.   Ownership of Five Percent or Less of a Class.
 
       If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X]
 
 
 
Item 6.   Ownership of More than Five Percent on Behalf of Another Person.
 
       Not applicable.
 
 
 
Item 7.   Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
 
       Not applicable.
 
 
 
Item 8.   Identification and Classification of Members of the Group.
 
       Not applicable.
 
 
 
Item 9.   Notice of Dissolution of Group.
 
       Not applicable.
 
 
 
Item 10.   Certification.
 
       By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
 

 
 
 

 
 
CUSIP No. 68230A106                   13G                          Page 5 of 5
 
 
 
 
SIGNATURE
 
      After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
 
Date: February 8, 2013
    
     
     
ABINGWORTH LLP
    
     
     
 
By:
/s/ James Abell
  
 
Name: James Abell
  
 
Title: Partner
  
 
 
 
 
 
Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)